At the largest hospital in Brooklyn, doctors are working to address disparities for patients facing advanced heart failure.

AngioDynamics announced today that it launched a new trial evaluating its AlphaVac F18 system in treating pulmonary embolism ...

The company’s RECOVER-AV trial is intended to further the adoption of its AlphaVac F1885 system in the European market.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vasc ...

AngioDynamics, Inc. announced the launch of the RECOVER AV trial of the company’s AlphaVac F18⁸⁵ multipurpose mecha ...

Boston Scientific (NYSE: BSX) received FDA approval to expand the indication for its current-generation Ingevity+ pacing ...

CVKD READ THE FULL CVKD RESEARCH REPORT We are initiating coverage of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) with a $30.00 valuation. Cadrenal is a biopharmaceutical developing innovative therapies ...

During the first quarter of fiscal year 2025 (“Q1 FY2025”), HeartSciences has seen material progress for both its MyoVista wav ECG TM device, MyoVista Insights TM cloud-platform and associated first ...

A total artificial heart implantation may be suggested in the event of LVAD failure. Learn what the SynCardia mechanical device could do for heart failure.

My condition was severe enough to warrant getting an LVAD (left ventricular assist device), which is basically a pump that’s ...

In a significant medical advancement for the state, Oklahoma Children’s Hospital OU Health has successfully implanted two ...